Brookdale Senior Living Inc.
NYSE:BKDMedical - Care Facilities
+$0.05 today
- Market cap
- $2.06B
- Beta
- 0.62
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 4.89M
Average 3.63M
BKD Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Brookdale Senior Living Inc.NYSE: BKD
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development remains negative
Q3 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How BKD compares with its peers on the latest reported figures
- BKD's LTM Sep 2026 research & development of $0 is the 5th highest of the 10 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for BKD, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $497M | +2.5% | +22.0% | 424.8% | |
| LTM Jun 2026 | $400.72M | -3.9% | +5.3% | 11118.8% | |
| LTM Jun 2026 | $289.55M | +15.9% | +30.4% | — | |
| LTM Sep 2026 | $252.23M | +33.2% | -5.7% | 138.2% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Oct 2026 | $0 | — | — | 0.0% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BKD) | $0 | +9.2% | +13.6% | 0.0% | |
Competitors are the stored peer set for BKD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.75B | 2.74B | 2.87B | 2.98B | 3.12B |
| Cost of Revenue | 2.26B | 2.23B | 2.12B | 2.18B | 2.48B |
| Gross Profit | 488.58M | 513.94M | 744.71M | 807.43M | 645.02M |
| Gross Margin | 17.8% | 18.7% | 26.0% | 27.1% | 20.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 359.27M | 333.89M | 384.52M | 386.63M | 349.89M |
| Operating Expenses | 705.52M | 556.63M | 726.3M | 760.9M | 627.86M |
| Depreciation & Amortization | 345.06M | 353.89M | 350.41M | 367.51M | 370.3M |
| EBITDA | 425.23M | 319.92M | 376.99M | 430.53M | 358.72M |
| EBITDA Margin | 15.5% | 11.7% | 13.1% | 14.4% | 11.5% |
| Operating Income | (216.94M) | (42.69M) | 18.41M | 46.53M | 17.17M |
| Operating Margin | -7.9% | -1.6% | 0.6% | 1.6% | 0.5% |
| Interest Income | 1.35M | 6.94M | 23.15M | 19.16M | 12.38M |
| Interest Expense | 187.69M | 205.93M | 231.72M | 243.29M | 253.11M |
| Other Income / Expenses | 109.41M | (197.21M) | (198.7M) | (243.88M) | (281.86M) |
| Income Before Tax | (107.53M) | (239.9M) | (180.29M) | (197.35M) | (264.7M) |
| Pre-Tax Margin | -3.9% | -8.7% | -6.3% | -6.6% | -8.5% |
| Income Tax Expense | (8.16M) | (1.56M) | 8.78M | 4.65M | (1.95M) |
| Net Income | (99.29M) | (238.43M) | (189.01M) | (201.94M) | (262.69M) |
| Net Margin | -3.6% | -8.7% | -6.6% | -6.8% | -8.4% |
| EPS (Basic) | (0.54) | (1.25) | (0.84) | (0.89) | (1.11) |
| EPS (Diluted) | (0.54) | (1.25) | (0.84) | (0.89) | (1.11) |
| Weighted Avg Shares | 184.98M | 190.46M | 225.21M | 227.53M | 234.33M |
| Weighted Avg Shares (Diluted) | 184.98M | 190.46M | 225.21M | 227.53M | 234.33M |
Brookdale Senior Living Inc.
NYSE:BKD
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.